adrien.roux 2939949659 Roux Adrien adrien.roux@hesge.ch en 1 On On

{"id":7855141,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24177,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA."},"en":{"id":24178,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA."},"de":{"id":24179,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA."}},"id":132704,"acronym":"P7 - Prime FNS - ALIMEA","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - ALIMEA.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1859969,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7855141,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132704}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7855051,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":14289,"title":"Prestations de service inSTI moins de CHF 5'000.- 2020.","description":"Prestations de service inSTI moins de CHF 5'000.- 2020."},"en":{"id":14290,"title":"Prestations de service inSTI moins de CHF 5'000.- 2020.","description":"Prestations de service inSTI moins de CHF 5'000.- 2020."},"de":{"id":14291,"title":"Prestations de service inSTI moins de CHF 5'000.- 2020.","description":"Prestations de service inSTI moins de CHF 5'000.- 2020."}},"id":101110,"acronym":"PS inSTI - 5'000.- 2020","mainTitle":"Prestations de service inSTI moins de CHF 5'000.- 2020.","mainDescription":"Prestations de service inSTI moins de CHF 5'000.- 2020.","value":null,"finished":true,"pilier":5,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1859955,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1859956,"name":"Triscone Gilles","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7855046,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"piero.pontelan","project":101110},{"id":7855047,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":false,"displayAcademicPartner":false,"displayProfessionalPartner":false,"collaborator":"nicola.giandome","project":101110},{"id":7855048,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":101110},{"id":7855049,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"harley.stoeckli","project":101110},{"id":7855050,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"sergio.marquez","project":101110},{"id":7855051,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":101110},{"id":7855052,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"axel.baxarias","project":101110},{"id":7855053,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"markrall.allado","project":101110},{"id":7855054,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"fabien.breda","project":101110},{"id":7855055,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"herve.sthioul","project":101110},{"id":7855056,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gilles.triscone","project":101110},{"id":7855057,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"jeanmarc.allenbac","project":101110},{"id":7855058,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"mathieu.difranco","project":101110},{"id":7855059,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"romain.boulande","project":101110},{"id":7855060,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"roberto.putzu","project":101110}],"dataHub":true,"startAt":"2020-01-01T00:00:00+01:00","endAt":"2020-12-31T00:00:00+01:00","fundingSource":"Clients divers; Kugler Bimetal SA; Rolex SA; Weinmann-Energies SA; HED Technologies S\u00e0rl; OCCS - GE D\u00c9COUVRE le mercredi; HEIA-FR; Cogito Instruments SA ; Piaget; MCE SWISS METROLOGY; FAS MEDIC SA; CEGELEC MOBILITY; ShemaTic S\u00e0rl; Haemon","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7851120,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24156,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant."},"en":{"id":24157,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant."},"de":{"id":24158,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant."}},"id":132686,"acronym":"P7 - Prime FNS - Cell-engineered modular implant","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Cell-engineered modular implant.","value":"4608.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1859125,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7851120,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132686}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7850770,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":21126,"title":"Prestations de service inSTI moins de CHF 5'000.- 2023.","description":"Prestations de service inSTI moins de CHF 5'000.- 2023."},"en":{"id":21127,"title":"Prestations de service inSTI moins de CHF 5'000.- 2023.","description":"Prestations de service inSTI moins de CHF 5'000.- 2023."},"de":{"id":21128,"title":"Prestations de service inSTI moins de CHF 5'000.- 2023.","description":"Prestations de service inSTI moins de CHF 5'000.- 2023."}},"id":125115,"acronym":"PS inSTI - 5'000.- 2023","mainTitle":"Prestations de service inSTI moins de CHF 5'000.- 2023.","mainDescription":"Prestations de service inSTI moins de CHF 5'000.- 2023.","value":null,"finished":true,"pilier":5,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1859064,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7850765,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":false,"displayAcademicPartner":false,"displayProfessionalPartner":false,"collaborator":"nicola.giandome","project":125115},{"id":7850766,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":125115},{"id":7850767,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"harley.stoeckli","project":125115},{"id":7850768,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"henrique.bastosdi","project":125115},{"id":7850769,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"jerome.exterman","project":125115},{"id":7850770,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":125115},{"id":7850771,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"axel.baxarias","project":125115},{"id":7850772,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"sebastie.carlesso","project":125115},{"id":7850773,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"florian.carrard","project":125115},{"id":7850774,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"markrall.allado","project":125115},{"id":7850775,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"fabien.breda","project":125115},{"id":7850776,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gilles.triscone","project":125115},{"id":7850777,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"theo.mercat","project":125115},{"id":7850778,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"margaux.delieutr","project":125115},{"id":7850779,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"romain.boulande","project":125115},{"id":7850780,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"frederic.bozon","project":125115},{"id":7850781,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"roberto.putzu","project":125115},{"id":7850782,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"enrico.pomarico","project":125115},{"id":7850783,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"cedric.schmidt","project":125115},{"id":7850784,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":false,"displayAcademicPartner":false,"displayProfessionalPartner":false,"collaborator":"jeremy.olivier","project":125115},{"id":7850785,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"christop.balistre","project":125115},{"id":7850786,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"roland.rozsnyo","project":125115},{"id":7850787,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"michel.lauria","project":125115}],"dataHub":true,"startAt":"2023-01-01T00:00:00+01:00","endAt":"2023-12-31T00:00:00+01:00","fundingSource":"Clients divers; Kugler Bimetal SA; Rolex SA; Weinmann-Energies SA; HED Technologies S\u00e0rl; OCCS - GE D\u00c9COUVRE le mercredi; HEIA-FR; Cogito Instruments SA ; Piaget; MCE SWISS METROLOGY; FAS MEDIC SA; Richemont International SA; CEGELEC MOBI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7850619,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24147,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI.\r\n","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI."},"en":{"id":24148,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI.\r\n","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI."},"de":{"id":24149,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI.\r\n","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI."}},"id":132633,"acronym":"P7 - Prime Swiss 3R Competence Center - BAMBI","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI.\r\n","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Swiss 3R Competence Center - BAMBI.","value":"2500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1859011,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"VS - Institut Sciences du vivant","class":"academique"},{"id":1859012,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7850618,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"jerome.exterman","project":132633},{"id":7850619,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132633},{"id":7850620,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"marcemil.pfeifer","project":132633}],"dataHub":true,"startAt":"2024-06-04T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7846917,"role":"CO","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":14111,"title":"PACMan_ Outil portable d'analyse de la fertilit\u00e9 masculine bas\u00e9e sur la mesure de la concentration et de la mobilit\u00e9 des spermatozo\u00efdes","description":"L'infertilit\u00e9 masculine est une r\u00e9alit\u00e9 de plus en plus inqui\u00e9tante comme le confirment des \u00e9tudes r\u00e9centes qui constatent une baisse de 50% de la concentration et de 60% du nombre total de spermatozo\u00efdes entre 1973 et 2011. Une baisse qualitative du sperme en termes de mobilit\u00e9 et de morphologie a aussi \u00e9t\u00e9 constat\u00e9e.\r\nActuellement les analyses d'infertilit\u00e9 masculine sont effectu\u00e9es dans des laboratoires sp\u00e9cialis\u00e9s dot\u00e9s d'\u00e9quipements de pointe, encombrants et on\u00e9reux. R\u00e9alis\u00e9es par du personnel qualifi\u00e9, elles sont chronophages et co\u00fbteuses. Pour ces raisons, ainsi que d'autres de type culturel, le public sous-estime le probl\u00e8me et m\u00e9conna\u00eet les possibilit\u00e9s de traitement.\r\nChez les animaux d'\u00e9levage l'ins\u00e9mination artificielle, bien que ch\u00e8re selon les esp\u00e8ces, est pr\u00e9pond\u00e9rante. De ce fait, les v\u00e9t\u00e9rinaires souhaiteraient pouvoir garantir \u00e0 leurs clients \u00e9leveurs la qualit\u00e9 des produits fournis par un test rapide et bon march\u00e9 \u00ab sur site \u00bb. Par ailleurs, chez certains animaux la qualit\u00e9 du sperme se d\u00e9grade si rapidement qu'une analyse en laboratoire est impossible (ex. : le sperme des truites a une dur\u00e9e de vie moyenne de 24s).\r\nL'objectif de ce projet a \u00e9t\u00e9 de concevoir un appareil portable \u00e0 bas co\u00fbt, utilisable hors des conditions de laboratoire, permettant d'effectuer les mesures essentielles de concentration et de motilit\u00e9 des spermatozo\u00efdes. La technologie d\u00e9velopp\u00e9e permet de garantir une analyse standardis\u00e9e, fiable et rapide. Les contacts pris avec des entreprises sp\u00e9cialis\u00e9es dans le domaine de la s\u00e9lection g\u00e9n\u00e9tique et de la reproduction animale (Swissgenetics) ou avec des institutions d\u00e9di\u00e9es \u00e0 l'\u00e9tude du monde animal (La Maison de la Rivi\u00e8re) ont montr\u00e9 leur int\u00e9r\u00eat par rapport \u00e0 notre appareil. \u00c9galement l'int\u00e9r\u00eat est marqu\u00e9 du c\u00f4t\u00e9 des fournisseurs (de logiciel et de mat\u00e9riel) ainsi que des laboratoires actifs dans le domaine de la reproduction humaine (AKYMed, Inndix).\r\nPour garantir un co\u00fbt minimum et son accessibilit\u00e9, l'appareil con\u00e7u et d\u00e9velopp\u00e9 se limite aux parties optiques et m\u00e9caniques strictement n\u00e9cessaires, il est accompagn\u00e9 d'une application mobile regroupant les fonctionnalit\u00e9s n\u00e9cessitant une puissance de calcul et les interactions avec l'utilisateur. En particulier l'application mobile permet \u00e0 l'utilisateur de contr\u00f4ler l'appareil, elle le guide lors du processus d'acquisition des images, elle effectue l'analyse des images, et finalement elle restitue les r\u00e9sultats en quelques secondes.\r\nL'instrument a \u00e9t\u00e9 test\u00e9 avec des \u00e9chantillons de sperme de diff\u00e9rentes esp\u00e8ces, en particulier avec des \u00e9chantillons de taureau sur lesquels les param\u00e8tres de concentration et de motilit\u00e9 mesur\u00e9s avec notre dispositif (hardware + algorithmes) ont \u00e9t\u00e9 valid\u00e9s en les comparant avec ceux obtenus avec un microscope \u00e0 contraste de phase standard et un logiciel CASA (Computer-Assisted Sperm Analysis) commercial, selon les normes de l'OMS.\r\nLa solution propos\u00e9e se diff\u00e9rencie des appareils similaires existants sur le march\u00e9 en apportant, en plus de la mesure de la concentration, celle de la motilit\u00e9. Elle ouvre \u00e9galement la possibilit\u00e9 de consid\u00e9rer l'utilisation de notre appareil sur le march\u00e9 de la reproduction humaine. \r\nUne valorisation de l'instrument est en cours de discussion avec la soci\u00e9t\u00e9 AKYmed S\u00e0rl, leader suisse des logiciels CASA qui est int\u00e9ress\u00e9e \u00e0 pouvoir continuer le d\u00e9veloppement de notre technologie dans le cadre d'un projet Innosuisse.\r\n"},"en":{"id":14112,"title":"PACMan_ Outil portable d'analyse de la fertilit\u00e9 masculine bas\u00e9e sur la mesure de la concentration et de la mobilit\u00e9 des spermatozo\u00efdes","description":"L'infertilit\u00e9 masculine est une r\u00e9alit\u00e9 de plus en plus inqui\u00e9tante comme le confirment des \u00e9tudes r\u00e9centes qui constatent une baisse de 50% de la concentration et de 60% du nombre total de spermatozo\u00efdes entre 1973 et 2011. Une baisse qualitative du sperme en termes de mobilit\u00e9 et de morphologie a aussi \u00e9t\u00e9 constat\u00e9e.\r\nActuellement les analyses d'infertilit\u00e9 masculine sont effectu\u00e9es dans des laboratoires sp\u00e9cialis\u00e9s dot\u00e9s d'\u00e9quipements de pointe, encombrants et on\u00e9reux. R\u00e9alis\u00e9es par du personnel qualifi\u00e9, elles sont chronophages et co\u00fbteuses. Pour ces raisons, ainsi que d'autres de type culturel, le public sous-estime le probl\u00e8me et m\u00e9conna\u00eet les possibilit\u00e9s de traitement.\r\nChez les animaux d'\u00e9levage l'ins\u00e9mination artificielle, bien que ch\u00e8re selon les esp\u00e8ces, est pr\u00e9pond\u00e9rante. De ce fait, les v\u00e9t\u00e9rinaires souhaiteraient pouvoir garantir \u00e0 leurs clients \u00e9leveurs la qualit\u00e9 des produits fournis par un test rapide et bon march\u00e9 \u00ab sur site \u00bb. Par ailleurs, chez certains animaux la qualit\u00e9 du sperme se d\u00e9grade si rapidement qu'une analyse en laboratoire est impossible (ex. : le sperme des truites a une dur\u00e9e de vie moyenne de 24s).\r\nL'objectif de ce projet a \u00e9t\u00e9 de concevoir un appareil portable \u00e0 bas co\u00fbt, utilisable hors des conditions de laboratoire, permettant d'effectuer les mesures essentielles de concentration et de motilit\u00e9 des spermatozo\u00efdes. La technologie d\u00e9velopp\u00e9e permet de garantir une analyse standardis\u00e9e, fiable et rapide. Les contacts pris avec des entreprises sp\u00e9cialis\u00e9es dans le domaine de la s\u00e9lection g\u00e9n\u00e9tique et de la reproduction animale (Swissgenetics) ou avec des institutions d\u00e9di\u00e9es \u00e0 l'\u00e9tude du monde animal (La Maison de la Rivi\u00e8re) ont montr\u00e9 leur int\u00e9r\u00eat par rapport \u00e0 notre appareil. \u00c9galement l'int\u00e9r\u00eat est marqu\u00e9 du c\u00f4t\u00e9 des fournisseurs (de logiciel et de mat\u00e9riel) ainsi que des laboratoires actifs dans le domaine de la reproduction humaine (AKYMed, Inndix).\r\nPour garantir un co\u00fbt minimum et son accessibilit\u00e9, l'appareil con\u00e7u et d\u00e9velopp\u00e9 se limite aux parties optiques et m\u00e9caniques strictement n\u00e9cessaires, il est accompagn\u00e9 d'une application mobile regroupant les fonctionnalit\u00e9s n\u00e9cessitant une puissance de calcul et les interactions avec l'utilisateur. En particulier l'application mobile permet \u00e0 l'utilisateur de contr\u00f4ler l'appareil, elle le guide lors du processus d'acquisition des images, elle effectue l'analyse des images, et finalement elle restitue les r\u00e9sultats en quelques secondes.\r\nL'instrument a \u00e9t\u00e9 test\u00e9 avec des \u00e9chantillons de sperme de diff\u00e9rentes esp\u00e8ces, en particulier avec des \u00e9chantillons de taureau sur lesquels les param\u00e8tres de concentration et de motilit\u00e9 mesur\u00e9s avec notre dispositif (hardware + algorithmes) ont \u00e9t\u00e9 valid\u00e9s en les comparant avec ceux obtenus avec un microscope \u00e0 contraste de phase standard et un logiciel CASA (Computer-Assisted Sperm Analysis) commercial, selon les normes de l'OMS.\r\nLa solution propos\u00e9e se diff\u00e9rencie des appareils similaires existants sur le march\u00e9 en apportant, en plus de la mesure de la concentration, celle de la motilit\u00e9. Elle ouvre \u00e9galement la possibilit\u00e9 de consid\u00e9rer l'utilisation de notre appareil sur le march\u00e9 de la reproduction humaine. \r\nUne valorisation de l'instrument est en cours de discussion avec la soci\u00e9t\u00e9 AKYmed S\u00e0rl, leader suisse des logiciels CASA qui est int\u00e9ress\u00e9e \u00e0 pouvoir continuer le d\u00e9veloppement de notre technologie dans le cadre d'un projet Innosuisse.\r\n"},"de":{"id":14113,"title":"PACMan_ Outil portable d'analyse de la fertilit\u00e9 masculine bas\u00e9e sur la mesure de la concentration et de la mobilit\u00e9 des spermatozo\u00efdes","description":"L'infertilit\u00e9 masculine est une r\u00e9alit\u00e9 de plus en plus inqui\u00e9tante comme le confirment des \u00e9tudes r\u00e9centes qui constatent une baisse de 50% de la concentration et de 60% du nombre total de spermatozo\u00efdes entre 1973 et 2011. Une baisse qualitative du sperme en termes de mobilit\u00e9 et de morphologie a aussi \u00e9t\u00e9 constat\u00e9e.\r\nActuellement les analyses d'infertilit\u00e9 masculine sont effectu\u00e9es dans des laboratoires sp\u00e9cialis\u00e9s dot\u00e9s d'\u00e9quipements de pointe, encombrants et on\u00e9reux. R\u00e9alis\u00e9es par du personnel qualifi\u00e9, elles sont chronophages et co\u00fbteuses. Pour ces raisons, ainsi que d'autres de type culturel, le public sous-estime le probl\u00e8me et m\u00e9conna\u00eet les possibilit\u00e9s de traitement.\r\nChez les animaux d'\u00e9levage l'ins\u00e9mination artificielle, bien que ch\u00e8re selon les esp\u00e8ces, est pr\u00e9pond\u00e9rante. De ce fait, les v\u00e9t\u00e9rinaires souhaiteraient pouvoir garantir \u00e0 leurs clients \u00e9leveurs la qualit\u00e9 des produits fournis par un test rapide et bon march\u00e9 \u00ab sur site \u00bb. Par ailleurs, chez certains animaux la qualit\u00e9 du sperme se d\u00e9grade si rapidement qu'une analyse en laboratoire est impossible (ex. : le sperme des truites a une dur\u00e9e de vie moyenne de 24s).\r\nL'objectif de ce projet a \u00e9t\u00e9 de concevoir un appareil portable \u00e0 bas co\u00fbt, utilisable hors des conditions de laboratoire, permettant d'effectuer les mesures essentielles de concentration et de motilit\u00e9 des spermatozo\u00efdes. La technologie d\u00e9velopp\u00e9e permet de garantir une analyse standardis\u00e9e, fiable et rapide. Les contacts pris avec des entreprises sp\u00e9cialis\u00e9es dans le domaine de la s\u00e9lection g\u00e9n\u00e9tique et de la reproduction animale (Swissgenetics) ou avec des institutions d\u00e9di\u00e9es \u00e0 l'\u00e9tude du monde animal (La Maison de la Rivi\u00e8re) ont montr\u00e9 leur int\u00e9r\u00eat par rapport \u00e0 notre appareil. \u00c9galement l'int\u00e9r\u00eat est marqu\u00e9 du c\u00f4t\u00e9 des fournisseurs (de logiciel et de mat\u00e9riel) ainsi que des laboratoires actifs dans le domaine de la reproduction humaine (AKYMed, Inndix).\r\nPour garantir un co\u00fbt minimum et son accessibilit\u00e9, l'appareil con\u00e7u et d\u00e9velopp\u00e9 se limite aux parties optiques et m\u00e9caniques strictement n\u00e9cessaires, il est accompagn\u00e9 d'une application mobile regroupant les fonctionnalit\u00e9s n\u00e9cessitant une puissance de calcul et les interactions avec l'utilisateur. En particulier l'application mobile permet \u00e0 l'utilisateur de contr\u00f4ler l'appareil, elle le guide lors du processus d'acquisition des images, elle effectue l'analyse des images, et finalement elle restitue les r\u00e9sultats en quelques secondes.\r\nL'instrument a \u00e9t\u00e9 test\u00e9 avec des \u00e9chantillons de sperme de diff\u00e9rentes esp\u00e8ces, en particulier avec des \u00e9chantillons de taureau sur lesquels les param\u00e8tres de concentration et de motilit\u00e9 mesur\u00e9s avec notre dispositif (hardware + algorithmes) ont \u00e9t\u00e9 valid\u00e9s en les comparant avec ceux obtenus avec un microscope \u00e0 contraste de phase standard et un logiciel CASA (Computer-Assisted Sperm Analysis) commercial, selon les normes de l'OMS.\r\nLa solution propos\u00e9e se diff\u00e9rencie des appareils similaires existants sur le march\u00e9 en apportant, en plus de la mesure de la concentration, celle de la motilit\u00e9. Elle ouvre \u00e9galement la possibilit\u00e9 de consid\u00e9rer l'utilisation de notre appareil sur le march\u00e9 de la reproduction humaine. \r\nUne valorisation de l'instrument est en cours de discussion avec la soci\u00e9t\u00e9 AKYmed S\u00e0rl, leader suisse des logiciels CASA qui est int\u00e9ress\u00e9e \u00e0 pouvoir continuer le d\u00e9veloppement de notre technologie dans le cadre d'un projet Innosuisse.\r\n"}},"id":99620,"acronym":"PACMan","mainTitle":"PACMan_ Outil portable d'analyse de la fertilit\u00e9 masculine bas\u00e9e sur la mesure de la concentration et de la mobilit\u00e9 des spermatozo\u00efdes","mainDescription":"L'infertilit\u00e9 masculine est une r\u00e9alit\u00e9 de plus en plus inqui\u00e9tante comme le confirment des \u00e9tudes r\u00e9centes qui constatent une baisse de 50% de la concentration et de 60% du nombre total de spermatozo\u00efdes entre 1973 et 2011. Une baisse qualitative du sperme en termes de mobilit\u00e9 et de morphologie a aussi \u00e9t\u00e9 constat\u00e9e.\r\nActuellement les analyses d'infertilit\u00e9 masculine sont effectu\u00e9es dans des laboratoires sp\u00e9cialis\u00e9s dot\u00e9s d'\u00e9quipements de pointe, encombrants et on\u00e9reux. R\u00e9alis\u00e9es par du personnel qualifi\u00e9, elles sont chronophages et co\u00fbteuses. Pour ces raisons, ainsi que d'autres de type culturel, le public sous-estime le probl\u00e8me et m\u00e9conna\u00eet les possibilit\u00e9s de traitement.\r\nChez les animaux d'\u00e9levage l'ins\u00e9mination artificielle, bien que ch\u00e8re selon les esp\u00e8ces, est pr\u00e9pond\u00e9rante. De ce fait, les v\u00e9t\u00e9rinaires souhaiteraient pouvoir garantir \u00e0 leurs clients \u00e9leveurs la qualit\u00e9 des produits fournis par un test rapide et bon march\u00e9 \u00ab sur site \u00bb. Par ailleurs, chez certains animaux la qualit\u00e9 du sperme se d\u00e9grade si rapidement qu'une analyse en laboratoire est impossible (ex. : le sperme des truites a une dur\u00e9e de vie moyenne de 24s).\r\nL'objectif de ce projet a \u00e9t\u00e9 de concevoir un appareil portable \u00e0 bas co\u00fbt, utilisable hors des conditions de laboratoire, permettant d'effectuer les mesures essentielles de concentration et de motilit\u00e9 des spermatozo\u00efdes. La technologie d\u00e9velopp\u00e9e permet de garantir une analyse standardis\u00e9e, fiable et rapide. Les contacts pris avec des entreprises sp\u00e9cialis\u00e9es dans le domaine de la s\u00e9lection g\u00e9n\u00e9tique et de la reproduction animale (Swissgenetics) ou avec des institutions d\u00e9di\u00e9es \u00e0 l'\u00e9tude du monde animal (La Maison de la Rivi\u00e8re) ont montr\u00e9 leur int\u00e9r\u00eat par rapport \u00e0 notre appareil. \u00c9galement l'int\u00e9r\u00eat est marqu\u00e9 du c\u00f4t\u00e9 des fournisseurs (de logiciel et de mat\u00e9riel) ainsi que des laboratoires actifs dans le domaine de la reproduction humaine (AKYMed, Inndix).\r\nPour garantir un co\u00fbt minimum et son accessibilit\u00e9, l'appareil con\u00e7u et d\u00e9velopp\u00e9 se limite aux parties optiques et m\u00e9caniques strictement n\u00e9cessaires, il est accompagn\u00e9 d'une application mobile regroupant les fonctionnalit\u00e9s n\u00e9cessitant une puissance de calcul et les interactions avec l'utilisateur. En particulier l'application mobile permet \u00e0 l'utilisateur de contr\u00f4ler l'appareil, elle le guide lors du processus d'acquisition des images, elle effectue l'analyse des images, et finalement elle restitue les r\u00e9sultats en quelques secondes.\r\nL'instrument a \u00e9t\u00e9 test\u00e9 avec des \u00e9chantillons de sperme de diff\u00e9rentes esp\u00e8ces, en particulier avec des \u00e9chantillons de taureau sur lesquels les param\u00e8tres de concentration et de motilit\u00e9 mesur\u00e9s avec notre dispositif (hardware + algorithmes) ont \u00e9t\u00e9 valid\u00e9s en les comparant avec ceux obtenus avec un microscope \u00e0 contraste de phase standard et un logiciel CASA (Computer-Assisted Sperm Analysis) commercial, selon les normes de l'OMS.\r\nLa solution propos\u00e9e se diff\u00e9rencie des appareils similaires existants sur le march\u00e9 en apportant, en plus de la mesure de la concentration, celle de la motilit\u00e9. Elle ouvre \u00e9galement la possibilit\u00e9 de consid\u00e9rer l'utilisation de notre appareil sur le march\u00e9 de la reproduction humaine. \r\nUne valorisation de l'instrument est en cours de discussion avec la soci\u00e9t\u00e9 AKYmed S\u00e0rl, leader suisse des logiciels CASA qui est int\u00e9ress\u00e9e \u00e0 pouvoir continuer le d\u00e9veloppement de notre technologie dans le cadre d'un projet Innosuisse.\r\n","value":"145200.00","finished":true,"pilier":6,"url":null,"keywords":"Image Processing and Analysis, Male fertility, Mobile Health, Optical Image acquisition, Semen Analysis","disciplines":[],"axes":[],"partners":[{"id":1858097,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"ReDS","class":"academique"},{"id":1858098,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"IICT","class":"academique"},{"id":1858099,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7846911,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gregory.medwed","project":99620},{"id":7846912,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"fabien.dutoit","project":99620},{"id":7846913,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"enrico.petragli","project":99620},{"id":7846914,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"alberto.dassatti","project":99620},{"id":7846915,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"lauraele.raileanu","project":99620},{"id":7846916,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"loris.gomezbai","project":99620},{"id":7846917,"role":"CO","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":99620},{"id":7846918,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gregoire.bouiller","project":99620},{"id":7846919,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"olivier.cuisenai","project":99620},{"id":7846920,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"basile.vu","project":99620},{"id":7846921,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gregory.hanggi","project":99620},{"id":7846922,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"marc.heuschke","project":99620},{"id":7846923,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"antoine.rochat","project":99620},{"id":7846924,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"loic.dessaule","project":99620},{"id":7846925,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"elena.najdenov","project":99620}],"dataHub":true,"startAt":"2020-02-01T00:00:00+01:00","endAt":"2022-04-04T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7845792,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":10342,"title":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","description":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n"},"en":{"id":10343,"title":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","description":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n"},"de":{"id":10344,"title":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","description":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n"}},"id":66637,"acronym":"NanoReg2","mainTitle":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","mainDescription":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n","value":"365098.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1857835,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"GE Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture","class":"academique"},{"id":1857836,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1857837,"name":null,"confidential":false,"types":[{"id":2,"code":"TER"},{"id":5,"code":"TERRAIN"}],"institution":"Partenaires NanoReg2","class":"professionnel"},{"id":1857838,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7845791,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"michael.minelli","project":66637},{"id":7845792,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":66637},{"id":7845793,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":66637},{"id":7845794,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":66637}],"dataHub":true,"startAt":"2016-03-10T00:00:00+01:00","endAt":"2019-02-28T00:00:00+01:00","fundingSource":"SEFRI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7845579,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":9580,"title":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","description":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n"},"en":{"id":9581,"title":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","description":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n"},"de":{"id":9582,"title":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","description":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n"}},"id":51307,"acronym":"I1 - MEAZURE","mainTitle":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","mainDescription":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n","value":"211600.00","finished":true,"pilier":6,"url":null,"keywords":"Bio-impedance, Blood brain barrier, Central nervous system, Drug discovery, Neurotoxicity","disciplines":[],"axes":[],"partners":[{"id":1857748,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"ReDS","class":"academique"},{"id":1857749,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"VS - Institut Sciences du vivant","class":"academique"},{"id":1857750,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1857751,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"FR - EIA - Institut IPRINT","class":"academique"},{"id":1857752,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"Technologie d'interaction","class":"academique"},{"id":1857753,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7845573,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"lorenzo.pirrami","project":51307},{"id":7845574,"role":"CO","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"aicha.rizzotti","project":51307},{"id":7845575,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"anne.walker","project":51307},{"id":7845576,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"yann.thoma","project":51307},{"id":7845577,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"rick.wertenbr","project":51307},{"id":7845578,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"roland.scherwey","project":51307},{"id":7845579,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":51307},{"id":7845580,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"mike.meury","project":51307},{"id":7845581,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":51307},{"id":7845582,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"bruno.schnyder","project":51307},{"id":7845583,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"marco.mazza","project":51307},{"id":7845584,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":51307}],"dataHub":true,"startAt":"2015-12-15T00:00:00+01:00","endAt":"2017-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7845551,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":9451,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":9452,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":9453,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":53966,"acronym":"SCAHT-6","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"168500.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7845549,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":53966},{"id":7845550,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":53966},{"id":7845551,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":53966},{"id":7845552,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":53966}],"dataHub":true,"startAt":"2016-01-01T00:00:00+01:00","endAt":"2016-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7843020,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":23322,"title":"endoMetriosis Organoids to vOice up woman paiN.","description":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies. The Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of a robust endometrium co-culture in vitro model connected to a fluidic management system to automatically change hormone concentrations over time. After having validated this initial healthy endometrium model, we have interconnected to another compartment for the invaded organ.\r\nWe have characterized human epithelial (Ishikawa cells) and stromal cells (ESS-1 cells) and built a human physiological model of the endometrium. We have simulated different aspects of the female reproductive system such as survival and multiplication rate depending on various concentrations of two key hormones (Progesterone and Oestrogen). For the pathological endometriosis in vitro model, we confirmed the integration capacity of endometrial cells on a potentially invaded organ such as intestinal construct (Caco-2) or fibroblast cells. Altogether, we have generated proof of concept data, and we are currently presenting the work in several conferences (MPS, WC13, BMT) and a scientific conference paper (submitted BMT). From these valorisations, we aim to foster collaborations with different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop a more accurate model and develop new treatments and therapies for endometriosis, ultimately leading to better patient life.\r\n"},"en":{"id":23323,"title":"endoMetriosis Organoids to vOice up woman paiN.","description":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies. The Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of a robust endometrium co-culture in vitro model connected to a fluidic management system to automatically change hormone concentrations over time. After having validated this initial healthy endometrium model, we have interconnected to another compartment for the invaded organ.\r\nWe have characterized human epithelial (Ishikawa cells) and stromal cells (ESS-1 cells) and built a human physiological model of the endometrium. We have simulated different aspects of the female reproductive system such as survival and multiplication rate depending on various concentrations of two key hormones (Progesterone and Oestrogen). For the pathological endometriosis in vitro model, we confirmed the integration capacity of endometrial cells on a potentially invaded organ such as intestinal construct (Caco-2) or fibroblast cells. Altogether, we have generated proof of concept data, and we are currently presenting the work in several conferences (MPS, WC13, BMT) and a scientific conference paper (submitted BMT). From these valorisations, we aim to foster collaborations with different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop a more accurate model and develop new treatments and therapies for endometriosis, ultimately leading to better patient life.\r\n"},"de":{"id":23324,"title":"endoMetriosis Organoids to vOice up woman paiN.","description":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies. The Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of a robust endometrium co-culture in vitro model connected to a fluidic management system to automatically change hormone concentrations over time. After having validated this initial healthy endometrium model, we have interconnected to another compartment for the invaded organ.\r\nWe have characterized human epithelial (Ishikawa cells) and stromal cells (ESS-1 cells) and built a human physiological model of the endometrium. We have simulated different aspects of the female reproductive system such as survival and multiplication rate depending on various concentrations of two key hormones (Progesterone and Oestrogen). For the pathological endometriosis in vitro model, we confirmed the integration capacity of endometrial cells on a potentially invaded organ such as intestinal construct (Caco-2) or fibroblast cells. Altogether, we have generated proof of concept data, and we are currently presenting the work in several conferences (MPS, WC13, BMT) and a scientific conference paper (submitted BMT). From these valorisations, we aim to foster collaborations with different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop a more accurate model and develop new treatments and therapies for endometriosis, ultimately leading to better patient life.\r\n"}},"id":129917,"acronym":"JC - MOON","mainTitle":"endoMetriosis Organoids to vOice up woman paiN.","mainDescription":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies. The Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of a robust endometrium co-culture in vitro model connected to a fluidic management system to automatically change hormone concentrations over time. After having validated this initial healthy endometrium model, we have interconnected to another compartment for the invaded organ.\r\nWe have characterized human epithelial (Ishikawa cells) and stromal cells (ESS-1 cells) and built a human physiological model of the endometrium. We have simulated different aspects of the female reproductive system such as survival and multiplication rate depending on various concentrations of two key hormones (Progesterone and Oestrogen). For the pathological endometriosis in vitro model, we confirmed the integration capacity of endometrial cells on a potentially invaded organ such as intestinal construct (Caco-2) or fibroblast cells. Altogether, we have generated proof of concept data, and we are currently presenting the work in several conferences (MPS, WC13, BMT) and a scientific conference paper (submitted BMT). From these valorisations, we aim to foster collaborations with different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop a more accurate model and develop new treatments and therapies for endometriosis, ultimately leading to better patient life.\r\n","value":"100000.00","finished":true,"pilier":6,"url":null,"keywords":"Endometriosis, Endometrium, Organ-On-Chip, Woman Health, in vitro model","disciplines":[],"axes":[],"partners":[{"id":1857032,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7843020,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":129917},{"id":7843021,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"marc.heuschke","project":129917},{"id":7843022,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"joao.marques","project":129917}],"dataHub":true,"startAt":"2024-05-01T00:00:00+02:00","endAt":"2025-04-30T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7819942,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24033,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH."},"en":{"id":24034,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH."},"de":{"id":24035,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH."}},"id":132727,"acronym":"P3 - Prime Horizon EU - POLYTECH","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - POLYTECH.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1851441,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTNP","class":"academique"}],"collaborators":[{"id":7819939,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"maha.deebcoll","project":132727},{"id":7819940,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"pauline.daniere","project":132727},{"id":7819941,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"pascal.boivin","project":132727},{"id":7819942,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132727},{"id":7819943,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"cedric.deluz","project":132727},{"id":7819944,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"thomas.caloz","project":132727}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7811090,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":25209,"title":"Plateforme de tests pour microrobots","description":"Les microrobots mobiles de dimensions millim\u00e9triques, ou moins, font l'objet de nombreux d\u00e9veloppements prometteurs pour diverses applications. Dans le domaine m\u00e9dical, par exemple, les microrobots actionn\u00e9s \u00e0 distance, sans fil et sans contact, peuvent repr\u00e9senter une alternative \u00e0 l'utilisation de cath\u00e9ters ou d'endoscopes et \u00e0 certaines op\u00e9rations invasives bas\u00e9es sur des incisions. En raison de leur tr\u00e8s petite taille, ils peuvent atteindre des zones profondes et difficiles d'acc\u00e8s dans le corps humain sans endommager les tissus. Les microrobots peuvent aider au diagnostic ou au traitement de maladies en r\u00e9alisant des t\u00e2ches vari\u00e9es dans le corps humain ou pour un d\u00e9p\u00f4t localis\u00e9 de m\u00e9dicaments.\r\n\r\nComme ces microrobots, ou les microcapsules, sont trop petits pour embarquer des moteurs, des capteurs ou des sources d'\u00e9nergie, il faut recourir \u00e0 un actionnement et \u00e0 des capteurs externes. \r\n\r\nLe projet a pour objectif de r\u00e9aliser une plateforme de tests pour les microrobots magn\u00e9tiques. Il s'agira de d\u00e9velopper et tester un syst\u00e8me d'actionnement \u00e9lectromagn\u00e9tique, avec un ensemble de bobines de Helmholtz et de Maxwell, pour contr\u00f4ler \u00e0 distance les d\u00e9placements, l'orientation et l'actionnement du microrobot. Ce dernier sera plac\u00e9 dans un fluide, \u00e0 l'int\u00e9rieur d'un volume transparent ('30x10mm) de type laboratoire sur puce (Lab-on-Chip: LoC). La plateforme sera munie de cam\u00e9ras pour suivre les mouvements et les actions r\u00e9alis\u00e9es.\r\n\r\nUne micro-pince magn\u00e9tique \u00e0 aimants sera d\u00e9velopp\u00e9e, r\u00e9alis\u00e9e et test\u00e9e. L'orientation et le d\u00e9placement de cette micro-pince, dans les diff\u00e9rentes directions (X, Y et Z), seront r\u00e9alis\u00e9s \u00e0 distance par le champ \u00e9lectromagn\u00e9tique. Il sera possible d'ouvrir et de fermer la micro-pince pour d\u00e9poser ou prendre un composant. Diff\u00e9rentes trajectoires et diff\u00e9rentes op\u00e9rations seront r\u00e9alis\u00e9es pour tester et montrer les fonctionnalit\u00e9s.\r\n\r\nDans les environnements opaques, comme ceux impos\u00e9s par les tissus humains des applications in vivo, le suivi de position d'un microrobot en temps-r\u00e9el est difficile. Une m\u00e9thode bas\u00e9e sur la mesure d'imp\u00e9dance sera implant\u00e9e et test\u00e9e (EIT : Electrical Impedance Tomography). Cette m\u00e9thode, non-invasive et peu encombrante, n'est pas nocive pour la sant\u00e9. Elle pr\u00e9sente diff\u00e9rentes caract\u00e9ristiques int\u00e9ressantes pour diverses applications de diagnostic et de suivi m\u00e9dical. De petites \u00e9lectrodes seront dispos\u00e9es autour du LoC afin de localiser le microrobot en temps r\u00e9el. La pr\u00e9cision de mesure et le suivi de la trajectoire, en fonction de la taille du microrobot, ainsi que l'influence du champ \u00e9lectromagn\u00e9tique sur la mesure seront \u00e9valu\u00e9s.\r\n\r\nLa plateforme d'essais r\u00e9alis\u00e9e permettra de tester diff\u00e9rents microrobots et diff\u00e9rents microcomposants magn\u00e9tiques (capsules, pinces, microrobots flexibles, etc.). Elle pourra \u00eatre valoris\u00e9e aupr\u00e8s d'entreprises et de laboratoires de la r\u00e9gion, dont nombreux sont sp\u00e9cialis\u00e9s dans les domaines de la microm\u00e9canique, de la bio-ing\u00e9nierie et des \u00e9quipements m\u00e9dicaux.\r\n\r\nLa plateforme de tests avec le syst\u00e8me de contr\u00f4le magn\u00e9tique et la micro-pince seront d\u00e9velopp\u00e9s et r\u00e9alis\u00e9s \u00e0 la HEIG-VD. Les \u00e9lectrodes pour le LoC et le syst\u00e8me de mesure d'imp\u00e9dance seront d\u00e9velopp\u00e9s et test\u00e9s \u00e0 l'HEPIA.\r\n"},"en":{"id":25210,"title":"Plateforme de tests pour microrobots","description":"Les microrobots mobiles de dimensions millim\u00e9triques, ou moins, font l'objet de nombreux d\u00e9veloppements prometteurs pour diverses applications. Dans le domaine m\u00e9dical, par exemple, les microrobots actionn\u00e9s \u00e0 distance, sans fil et sans contact, peuvent repr\u00e9senter une alternative \u00e0 l'utilisation de cath\u00e9ters ou d'endoscopes et \u00e0 certaines op\u00e9rations invasives bas\u00e9es sur des incisions. En raison de leur tr\u00e8s petite taille, ils peuvent atteindre des zones profondes et difficiles d'acc\u00e8s dans le corps humain sans endommager les tissus. Les microrobots peuvent aider au diagnostic ou au traitement de maladies en r\u00e9alisant des t\u00e2ches vari\u00e9es dans le corps humain ou pour un d\u00e9p\u00f4t localis\u00e9 de m\u00e9dicaments.\r\n\r\nComme ces microrobots, ou les microcapsules, sont trop petits pour embarquer des moteurs, des capteurs ou des sources d'\u00e9nergie, il faut recourir \u00e0 un actionnement et \u00e0 des capteurs externes. \r\n\r\nLe projet a pour objectif de r\u00e9aliser une plateforme de tests pour les microrobots magn\u00e9tiques. Il s'agira de d\u00e9velopper et tester un syst\u00e8me d'actionnement \u00e9lectromagn\u00e9tique, avec un ensemble de bobines de Helmholtz et de Maxwell, pour contr\u00f4ler \u00e0 distance les d\u00e9placements, l'orientation et l'actionnement du microrobot. Ce dernier sera plac\u00e9 dans un fluide, \u00e0 l'int\u00e9rieur d'un volume transparent ('30x10mm) de type laboratoire sur puce (Lab-on-Chip: LoC). La plateforme sera munie de cam\u00e9ras pour suivre les mouvements et les actions r\u00e9alis\u00e9es.\r\n\r\nUne micro-pince magn\u00e9tique \u00e0 aimants sera d\u00e9velopp\u00e9e, r\u00e9alis\u00e9e et test\u00e9e. L'orientation et le d\u00e9placement de cette micro-pince, dans les diff\u00e9rentes directions (X, Y et Z), seront r\u00e9alis\u00e9s \u00e0 distance par le champ \u00e9lectromagn\u00e9tique. Il sera possible d'ouvrir et de fermer la micro-pince pour d\u00e9poser ou prendre un composant. Diff\u00e9rentes trajectoires et diff\u00e9rentes op\u00e9rations seront r\u00e9alis\u00e9es pour tester et montrer les fonctionnalit\u00e9s.\r\n\r\nDans les environnements opaques, comme ceux impos\u00e9s par les tissus humains des applications in vivo, le suivi de position d'un microrobot en temps-r\u00e9el est difficile. Une m\u00e9thode bas\u00e9e sur la mesure d'imp\u00e9dance sera implant\u00e9e et test\u00e9e (EIT : Electrical Impedance Tomography). Cette m\u00e9thode, non-invasive et peu encombrante, n'est pas nocive pour la sant\u00e9. Elle pr\u00e9sente diff\u00e9rentes caract\u00e9ristiques int\u00e9ressantes pour diverses applications de diagnostic et de suivi m\u00e9dical. De petites \u00e9lectrodes seront dispos\u00e9es autour du LoC afin de localiser le microrobot en temps r\u00e9el. La pr\u00e9cision de mesure et le suivi de la trajectoire, en fonction de la taille du microrobot, ainsi que l'influence du champ \u00e9lectromagn\u00e9tique sur la mesure seront \u00e9valu\u00e9s.\r\n\r\nLa plateforme d'essais r\u00e9alis\u00e9e permettra de tester diff\u00e9rents microrobots et diff\u00e9rents microcomposants magn\u00e9tiques (capsules, pinces, microrobots flexibles, etc.). Elle pourra \u00eatre valoris\u00e9e aupr\u00e8s d'entreprises et de laboratoires de la r\u00e9gion, dont nombreux sont sp\u00e9cialis\u00e9s dans les domaines de la microm\u00e9canique, de la bio-ing\u00e9nierie et des \u00e9quipements m\u00e9dicaux.\r\n\r\nLa plateforme de tests avec le syst\u00e8me de contr\u00f4le magn\u00e9tique et la micro-pince seront d\u00e9velopp\u00e9s et r\u00e9alis\u00e9s \u00e0 la HEIG-VD. Les \u00e9lectrodes pour le LoC et le syst\u00e8me de mesure d'imp\u00e9dance seront d\u00e9velopp\u00e9s et test\u00e9s \u00e0 l'HEPIA.\r\n"},"de":{"id":25211,"title":"Plateforme de tests pour microrobots","description":"Les microrobots mobiles de dimensions millim\u00e9triques, ou moins, font l'objet de nombreux d\u00e9veloppements prometteurs pour diverses applications. Dans le domaine m\u00e9dical, par exemple, les microrobots actionn\u00e9s \u00e0 distance, sans fil et sans contact, peuvent repr\u00e9senter une alternative \u00e0 l'utilisation de cath\u00e9ters ou d'endoscopes et \u00e0 certaines op\u00e9rations invasives bas\u00e9es sur des incisions. En raison de leur tr\u00e8s petite taille, ils peuvent atteindre des zones profondes et difficiles d'acc\u00e8s dans le corps humain sans endommager les tissus. Les microrobots peuvent aider au diagnostic ou au traitement de maladies en r\u00e9alisant des t\u00e2ches vari\u00e9es dans le corps humain ou pour un d\u00e9p\u00f4t localis\u00e9 de m\u00e9dicaments.\r\n\r\nComme ces microrobots, ou les microcapsules, sont trop petits pour embarquer des moteurs, des capteurs ou des sources d'\u00e9nergie, il faut recourir \u00e0 un actionnement et \u00e0 des capteurs externes. \r\n\r\nLe projet a pour objectif de r\u00e9aliser une plateforme de tests pour les microrobots magn\u00e9tiques. Il s'agira de d\u00e9velopper et tester un syst\u00e8me d'actionnement \u00e9lectromagn\u00e9tique, avec un ensemble de bobines de Helmholtz et de Maxwell, pour contr\u00f4ler \u00e0 distance les d\u00e9placements, l'orientation et l'actionnement du microrobot. Ce dernier sera plac\u00e9 dans un fluide, \u00e0 l'int\u00e9rieur d'un volume transparent ('30x10mm) de type laboratoire sur puce (Lab-on-Chip: LoC). La plateforme sera munie de cam\u00e9ras pour suivre les mouvements et les actions r\u00e9alis\u00e9es.\r\n\r\nUne micro-pince magn\u00e9tique \u00e0 aimants sera d\u00e9velopp\u00e9e, r\u00e9alis\u00e9e et test\u00e9e. L'orientation et le d\u00e9placement de cette micro-pince, dans les diff\u00e9rentes directions (X, Y et Z), seront r\u00e9alis\u00e9s \u00e0 distance par le champ \u00e9lectromagn\u00e9tique. Il sera possible d'ouvrir et de fermer la micro-pince pour d\u00e9poser ou prendre un composant. Diff\u00e9rentes trajectoires et diff\u00e9rentes op\u00e9rations seront r\u00e9alis\u00e9es pour tester et montrer les fonctionnalit\u00e9s.\r\n\r\nDans les environnements opaques, comme ceux impos\u00e9s par les tissus humains des applications in vivo, le suivi de position d'un microrobot en temps-r\u00e9el est difficile. Une m\u00e9thode bas\u00e9e sur la mesure d'imp\u00e9dance sera implant\u00e9e et test\u00e9e (EIT : Electrical Impedance Tomography). Cette m\u00e9thode, non-invasive et peu encombrante, n'est pas nocive pour la sant\u00e9. Elle pr\u00e9sente diff\u00e9rentes caract\u00e9ristiques int\u00e9ressantes pour diverses applications de diagnostic et de suivi m\u00e9dical. De petites \u00e9lectrodes seront dispos\u00e9es autour du LoC afin de localiser le microrobot en temps r\u00e9el. La pr\u00e9cision de mesure et le suivi de la trajectoire, en fonction de la taille du microrobot, ainsi que l'influence du champ \u00e9lectromagn\u00e9tique sur la mesure seront \u00e9valu\u00e9s.\r\n\r\nLa plateforme d'essais r\u00e9alis\u00e9e permettra de tester diff\u00e9rents microrobots et diff\u00e9rents microcomposants magn\u00e9tiques (capsules, pinces, microrobots flexibles, etc.). Elle pourra \u00eatre valoris\u00e9e aupr\u00e8s d'entreprises et de laboratoires de la r\u00e9gion, dont nombreux sont sp\u00e9cialis\u00e9s dans les domaines de la microm\u00e9canique, de la bio-ing\u00e9nierie et des \u00e9quipements m\u00e9dicaux.\r\n\r\nLa plateforme de tests avec le syst\u00e8me de contr\u00f4le magn\u00e9tique et la micro-pince seront d\u00e9velopp\u00e9s et r\u00e9alis\u00e9s \u00e0 la HEIG-VD. Les \u00e9lectrodes pour le LoC et le syst\u00e8me de mesure d'imp\u00e9dance seront d\u00e9velopp\u00e9s et test\u00e9s \u00e0 l'HEPIA.\r\n"}},"id":134963,"acronym":"MicRoBio","mainTitle":"Plateforme de tests pour microrobots","mainDescription":"Les microrobots mobiles de dimensions millim\u00e9triques, ou moins, font l'objet de nombreux d\u00e9veloppements prometteurs pour diverses applications. Dans le domaine m\u00e9dical, par exemple, les microrobots actionn\u00e9s \u00e0 distance, sans fil et sans contact, peuvent repr\u00e9senter une alternative \u00e0 l'utilisation de cath\u00e9ters ou d'endoscopes et \u00e0 certaines op\u00e9rations invasives bas\u00e9es sur des incisions. En raison de leur tr\u00e8s petite taille, ils peuvent atteindre des zones profondes et difficiles d'acc\u00e8s dans le corps humain sans endommager les tissus. Les microrobots peuvent aider au diagnostic ou au traitement de maladies en r\u00e9alisant des t\u00e2ches vari\u00e9es dans le corps humain ou pour un d\u00e9p\u00f4t localis\u00e9 de m\u00e9dicaments.\r\n\r\nComme ces microrobots, ou les microcapsules, sont trop petits pour embarquer des moteurs, des capteurs ou des sources d'\u00e9nergie, il faut recourir \u00e0 un actionnement et \u00e0 des capteurs externes. \r\n\r\nLe projet a pour objectif de r\u00e9aliser une plateforme de tests pour les microrobots magn\u00e9tiques. Il s'agira de d\u00e9velopper et tester un syst\u00e8me d'actionnement \u00e9lectromagn\u00e9tique, avec un ensemble de bobines de Helmholtz et de Maxwell, pour contr\u00f4ler \u00e0 distance les d\u00e9placements, l'orientation et l'actionnement du microrobot. Ce dernier sera plac\u00e9 dans un fluide, \u00e0 l'int\u00e9rieur d'un volume transparent ('30x10mm) de type laboratoire sur puce (Lab-on-Chip: LoC). La plateforme sera munie de cam\u00e9ras pour suivre les mouvements et les actions r\u00e9alis\u00e9es.\r\n\r\nUne micro-pince magn\u00e9tique \u00e0 aimants sera d\u00e9velopp\u00e9e, r\u00e9alis\u00e9e et test\u00e9e. L'orientation et le d\u00e9placement de cette micro-pince, dans les diff\u00e9rentes directions (X, Y et Z), seront r\u00e9alis\u00e9s \u00e0 distance par le champ \u00e9lectromagn\u00e9tique. Il sera possible d'ouvrir et de fermer la micro-pince pour d\u00e9poser ou prendre un composant. Diff\u00e9rentes trajectoires et diff\u00e9rentes op\u00e9rations seront r\u00e9alis\u00e9es pour tester et montrer les fonctionnalit\u00e9s.\r\n\r\nDans les environnements opaques, comme ceux impos\u00e9s par les tissus humains des applications in vivo, le suivi de position d'un microrobot en temps-r\u00e9el est difficile. Une m\u00e9thode bas\u00e9e sur la mesure d'imp\u00e9dance sera implant\u00e9e et test\u00e9e (EIT : Electrical Impedance Tomography). Cette m\u00e9thode, non-invasive et peu encombrante, n'est pas nocive pour la sant\u00e9. Elle pr\u00e9sente diff\u00e9rentes caract\u00e9ristiques int\u00e9ressantes pour diverses applications de diagnostic et de suivi m\u00e9dical. De petites \u00e9lectrodes seront dispos\u00e9es autour du LoC afin de localiser le microrobot en temps r\u00e9el. La pr\u00e9cision de mesure et le suivi de la trajectoire, en fonction de la taille du microrobot, ainsi que l'influence du champ \u00e9lectromagn\u00e9tique sur la mesure seront \u00e9valu\u00e9s.\r\n\r\nLa plateforme d'essais r\u00e9alis\u00e9e permettra de tester diff\u00e9rents microrobots et diff\u00e9rents microcomposants magn\u00e9tiques (capsules, pinces, microrobots flexibles, etc.). Elle pourra \u00eatre valoris\u00e9e aupr\u00e8s d'entreprises et de laboratoires de la r\u00e9gion, dont nombreux sont sp\u00e9cialis\u00e9s dans les domaines de la microm\u00e9canique, de la bio-ing\u00e9nierie et des \u00e9quipements m\u00e9dicaux.\r\n\r\nLa plateforme de tests avec le syst\u00e8me de contr\u00f4le magn\u00e9tique et la micro-pince seront d\u00e9velopp\u00e9s et r\u00e9alis\u00e9s \u00e0 la HEIG-VD. Les \u00e9lectrodes pour le LoC et le syst\u00e8me de mesure d'imp\u00e9dance seront d\u00e9velopp\u00e9s et test\u00e9s \u00e0 l'HEPIA.\r\n","value":"220000.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1849205,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"},{"id":1849206,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"iE","class":"academique"},{"id":1849207,"name":"Besson Christophe","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"iE","class":"academique"}],"collaborators":[{"id":7811088,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"christop.besson","project":134963},{"id":7811089,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"alain.savary","project":134963},{"id":7811090,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":134963},{"id":7811091,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dario.principi","project":134963}],"dataHub":true,"startAt":"2025-03-02T00:00:00+01:00","endAt":"2026-08-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7787583,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":7504,"title":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","description":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)"},"en":{"id":7505,"title":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","description":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)"},"de":{"id":7506,"title":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","description":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)"}},"id":38396,"acronym":"13IMA-S38396-RadioBeam","mainTitle":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","mainDescription":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)","value":"250000.00","finished":true,"pilier":6,"url":null,"keywords":"Analyses microbiologiques","disciplines":[],"axes":[],"partners":[{"id":1843316,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1843317,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"Ing\u00e9nierie des surfaces","class":"academique"},{"id":1843318,"name":"Whitlow Harry","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"Ing\u00e9nierie des surfaces","class":"academique"}],"collaborators":[{"id":7787578,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"alexandr.kaempfer","project":38396},{"id":7787579,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"christia.broggini","project":38396},{"id":7787580,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"catherin.csefalva","project":38396},{"id":7787581,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"claudio.prieur","project":38396},{"id":7787582,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"stephan.ramseyer","project":38396},{"id":7787583,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":38396},{"id":7787584,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":38396}],"dataHub":true,"startAt":"2013-11-01T00:00:00+01:00","endAt":"2015-10-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7786839,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":7597,"title":"In vitro models for toxicity assessment\r\n","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and"},"en":{"id":7598,"title":"In vitro models for toxicity assessment\r\n","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and"},"de":{"id":7599,"title":"In vitro models for toxicity assessment\r\n","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and"}},"id":38824,"acronym":"SCAHT4_2014","mainTitle":"In vitro models for toxicity assessment\r\n","mainDescription":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and","value":"340000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7786837,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":38824},{"id":7786838,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":38824},{"id":7786839,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":38824},{"id":7786840,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":38824}],"dataHub":true,"startAt":"2014-04-01T00:00:00+02:00","endAt":"2014-12-31T00:00:00+01:00","fundingSource":"UNIGE; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7786583,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":7042,"title":"In vitro models for toxicity assessement.","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an"},"en":{"id":7043,"title":"In vitro models for toxicity assessement.","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an"},"de":{"id":7044,"title":"In vitro models for toxicity assessement.","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an"}},"id":36062,"acronym":"SCAHT 3","mainTitle":"In vitro models for toxicity assessement.","mainDescription":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an","value":"340000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7786581,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":36062},{"id":7786582,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":36062},{"id":7786583,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":36062},{"id":7786584,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"herve.sthioul","project":36062},{"id":7786585,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":36062}],"dataHub":true,"startAt":"2013-01-01T00:00:00+01:00","endAt":"2014-06-30T00:00:00+02:00","fundingSource":"hepia inSTI; Universit\u00e9 de Gen\u00e8ve; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7785921,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24186,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC."},"en":{"id":24187,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC."},"de":{"id":24188,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC."}},"id":132726,"acronym":"P3 - Prime Horizon EU - UNLOOC","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - UNLOOC.","value":"15000.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1842507,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7785921,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132726}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7782862,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24168,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE."},"en":{"id":24169,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE."},"de":{"id":24170,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE."}},"id":132703,"acronym":"P7 - Prime FNS - PARKINSONSDISEASE","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - PARKINSONSDISEASE.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1841655,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7782862,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132703}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7781239,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":19390,"title":"Proof of concept of a novel electrical stimulation device to enhance 3D Cartilage microtissue production to treat cartilage damage in a clinical trial.\r\n\r\n\r\n","description":"Cartilage damage has a very low capacity for self-repair and often evolves to osteoarthritis with an increasing prevalence due to aging and overweight people. Treatments are very limited and are only palliative to relieve the pain, with joint replacement being the final solution. Cartilage tissues engineered from the patient's own cells and resembling to native cartilage represent an attractive solution. Data from large animal models have been encouraging which led to the approval of the first-in-man study starting soon with the autologous tissues produced from Vanarix.\r\nCurrently, 3D cartilage microtissue production takes time and this time could be shortened by employing stimulation techniques to produce better quality tissues (size and biochemical composition). In this project, we proposed to develop and integrate a specifically designed electrical stimulation device for 96 well plates used to generate cartilage microtissues into an industrial system compatible with medical standard. This system will include electrodes and electronic device able to stimulate for a long period of time 96 microtissues.\r\nThe innovative system will allow for accurate, reliable, robust and rapid growth of engineered microtissues, will improve the manufacturing process and decrease the cost of production and will therefore render treatment more affordable. The high cost of cellular therapy is a barrier to its expansion and the project will strengthen Vanarix's position in the cell therapy market.\r\n\r\n"},"en":{"id":19391,"title":"Proof of concept of a novel electrical stimulation device to enhance 3D Cartilage microtissue production to treat cartilage damage in a clinical trial.\r\n\r\n\r\n","description":"Cartilage damage has a very low capacity for self-repair and often evolves to osteoarthritis with an increasing prevalence due to aging and overweight people. Treatments are very limited and are only palliative to relieve the pain, with joint replacement being the final solution. Cartilage tissues engineered from the patient's own cells and resembling to native cartilage represent an attractive solution. Data from large animal models have been encouraging which led to the approval of the first-in-man study starting soon with the autologous tissues produced from Vanarix.\r\nCurrently, 3D cartilage microtissue production takes time and this time could be shortened by employing stimulation techniques to produce better quality tissues (size and biochemical composition). In this project, we proposed to develop and integrate a specifically designed electrical stimulation device for 96 well plates used to generate cartilage microtissues into an industrial system compatible with medical standard. This system will include electrodes and electronic device able to stimulate for a long period of time 96 microtissues.\r\nThe innovative system will allow for accurate, reliable, robust and rapid growth of engineered microtissues, will improve the manufacturing process and decrease the cost of production and will therefore render treatment more affordable. The high cost of cellular therapy is a barrier to its expansion and the project will strengthen Vanarix's position in the cell therapy market.\r\n\r\n"},"de":{"id":19392,"title":"Proof of concept of a novel electrical stimulation device to enhance 3D Cartilage microtissue production to treat cartilage damage in a clinical trial.\r\n\r\n\r\n","description":"Cartilage damage has a very low capacity for self-repair and often evolves to osteoarthritis with an increasing prevalence due to aging and overweight people. Treatments are very limited and are only palliative to relieve the pain, with joint replacement being the final solution. Cartilage tissues engineered from the patient's own cells and resembling to native cartilage represent an attractive solution. Data from large animal models have been encouraging which led to the approval of the first-in-man study starting soon with the autologous tissues produced from Vanarix.\r\nCurrently, 3D cartilage microtissue production takes time and this time could be shortened by employing stimulation techniques to produce better quality tissues (size and biochemical composition). In this project, we proposed to develop and integrate a specifically designed electrical stimulation device for 96 well plates used to generate cartilage microtissues into an industrial system compatible with medical standard. This system will include electrodes and electronic device able to stimulate for a long period of time 96 microtissues.\r\nThe innovative system will allow for accurate, reliable, robust and rapid growth of engineered microtissues, will improve the manufacturing process and decrease the cost of production and will therefore render treatment more affordable. The high cost of cellular therapy is a barrier to its expansion and the project will strengthen Vanarix's position in the cell therapy market.\r\n\r\n"}},"id":118604,"acronym":"Vanarix","mainTitle":"Proof of concept of a novel electrical stimulation device to enhance 3D Cartilage microtissue production to treat cartilage damage in a clinical trial.\r\n\r\n\r\n","mainDescription":"Cartilage damage has a very low capacity for self-repair and often evolves to osteoarthritis with an increasing prevalence due to aging and overweight people. Treatments are very limited and are only palliative to relieve the pain, with joint replacement being the final solution. Cartilage tissues engineered from the patient's own cells and resembling to native cartilage represent an attractive solution. Data from large animal models have been encouraging which led to the approval of the first-in-man study starting soon with the autologous tissues produced from Vanarix.\r\nCurrently, 3D cartilage microtissue production takes time and this time could be shortened by employing stimulation techniques to produce better quality tissues (size and biochemical composition). In this project, we proposed to develop and integrate a specifically designed electrical stimulation device for 96 well plates used to generate cartilage microtissues into an industrial system compatible with medical standard. This system will include electrodes and electronic device able to stimulate for a long period of time 96 microtissues.\r\nThe innovative system will allow for accurate, reliable, robust and rapid growth of engineered microtissues, will improve the manufacturing process and decrease the cost of production and will therefore render treatment more affordable. The high cost of cellular therapy is a barrier to its expansion and the project will strengthen Vanarix's position in the cell therapy market.\r\n\r\n","value":"12666.66","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1841212,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1841213,"name":null,"confidential":false,"types":[{"id":2,"code":"TER"},{"id":5,"code":"TERRAIN"}],"institution":"Innosuisse - 20% Charges patronales","class":"professionnel"}],"collaborators":[{"id":7781239,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":118604},{"id":7781240,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gregoire.bouiller","project":118604}],"dataHub":true,"startAt":"2022-04-01T00:00:00+02:00","endAt":"2022-12-31T00:00:00+01:00","fundingSource":"Innosuisse","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7781035,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":22149,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - NucleaLink.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"en":{"id":22150,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - NucleaLink.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"de":{"id":22151,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - NucleaLink.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."}},"id":126293,"acronym":"P7 - Prime FNS - NucleaLink","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - NucleaLink.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1841122,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7781035,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":126293}],"dataHub":true,"startAt":"2023-05-11T00:00:00+02:00","endAt":"2026-08-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7778898,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":22143,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - FUNCTIONALOID.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"en":{"id":22144,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - FUNCTIONALOID.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"de":{"id":22145,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - FUNCTIONALOID.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."}},"id":126306,"acronym":"P7 - Prime FNS - FUNCTIONALOID","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - FUNCTIONALOID.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1840442,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7778898,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":126306}],"dataHub":true,"startAt":"2023-05-11T00:00:00+02:00","endAt":"2026-08-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7777852,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":22122,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Fondation - Mod. pigmentary retina.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"en":{"id":22123,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Fondation - Mod. pigmentary retina.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"de":{"id":22124,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Fondation - Mod. pigmentary retina.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."}},"id":126356,"acronym":"P7 - Prime Fondation - Mod. pigmentary retina","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Fondation - Mod. pigmentary retina.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1840157,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7777852,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":126356}],"dataHub":true,"startAt":"2023-05-11T00:00:00+02:00","endAt":"2026-08-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7775233,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":22113,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - GliaX-3D MEA Platform.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"en":{"id":22114,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - GliaX-3D MEA Platform.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"de":{"id":22115,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - GliaX-3D MEA Platform.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."}},"id":126300,"acronym":"P3 - Prime Innosuisse - GliaX-3D MEA Platform","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - GliaX-3D MEA Platform.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1839543,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"IICT","class":"academique"},{"id":1839544,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7775233,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":126300},{"id":7775234,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"andres.perezuri","project":126300}],"dataHub":true,"startAt":"2023-05-11T00:00:00+02:00","endAt":"2026-08-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7771726,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":23964,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS."},"en":{"id":23965,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS."},"de":{"id":23966,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS."}},"id":132780,"acronym":"P3 - Prime Innosuisse - MPS","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - MPS.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1838633,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7771725,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"jerome.exterman","project":132780},{"id":7771726,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132780},{"id":7771727,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"victor.cochet","project":132780}],"dataHub":true,"startAt":"2024-06-10T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7768844,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":23946,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT."},"en":{"id":23947,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT."},"de":{"id":23948,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT."}},"id":132739,"acronym":"P3 - Prime Horizon EU - DISH-PREDICT","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Horizon EU - DISH-PREDICT.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1838125,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7768844,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132739}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7768264,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":22080,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - New bio-impedance device.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"en":{"id":22081,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - New bio-impedance device.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."},"de":{"id":22082,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - New bio-impedance device.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers."}},"id":126303,"acronym":"P3 - Prime Innosuisse - New bio-impedance device","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime Innosuisse - New bio-impedance device.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers.","value":"7500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1837945,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7768264,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":126303}],"dataHub":true,"startAt":"2023-05-11T00:00:00+02:00","endAt":"2026-08-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7767137,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24138,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair."},"en":{"id":24139,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair."},"de":{"id":24140,"title":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair.","description":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair."}},"id":132700,"acronym":"P7 - Prime FNS - Gopalakrishnan Nair","mainTitle":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair.","mainDescription":"Programme de soutien au d\u00e9p\u00f4t de projets li\u00e9s \u00e0 l'obtention de fonds de tiers ; Prime FNS - Gopalakrishnan Nair.","value":"2304.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1837650,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7767137,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":132700}],"dataHub":true,"startAt":"2024-06-05T00:00:00+02:00","endAt":"2025-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7765592,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":24880,"title":"EndoMetriosis Organoids to vOice up woman paiN.","description":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies.\r\n\r\nThe Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of three interconnected modules, each dedicated to simulating different aspects of the female reproductive system, specifically emphasising endometriosis. By providing a more accurate model of the female reproductive organs and improving our understanding of endometriosis, this project will allow researchers to identify new drug targets and biomarkers, ultimately leading to better patient treatments.\r\n\r\nIn addition, the Moon project could foster HES-SO collaborations among different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop new treatments and therapies for endometriosis. Moreover, this interdisciplinary approach may pave the way for creating similar projects in other areas of medical research, ultimately improving the quality of healthcare and advancing medical science."},"en":{"id":24881,"title":"EndoMetriosis Organoids to vOice up woman paiN.","description":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies.\r\n\r\nThe Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of three interconnected modules, each dedicated to simulating different aspects of the female reproductive system, specifically emphasising endometriosis. By providing a more accurate model of the female reproductive organs and improving our understanding of endometriosis, this project will allow researchers to identify new drug targets and biomarkers, ultimately leading to better patient treatments.\r\n\r\nIn addition, the Moon project could foster HES-SO collaborations among different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop new treatments and therapies for endometriosis. Moreover, this interdisciplinary approach may pave the way for creating similar projects in other areas of medical research, ultimately improving the quality of healthcare and advancing medical science."},"de":{"id":24882,"title":"EndoMetriosis Organoids to vOice up woman paiN.","description":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies.\r\n\r\nThe Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of three interconnected modules, each dedicated to simulating different aspects of the female reproductive system, specifically emphasising endometriosis. By providing a more accurate model of the female reproductive organs and improving our understanding of endometriosis, this project will allow researchers to identify new drug targets and biomarkers, ultimately leading to better patient treatments.\r\n\r\nIn addition, the Moon project could foster HES-SO collaborations among different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop new treatments and therapies for endometriosis. Moreover, this interdisciplinary approach may pave the way for creating similar projects in other areas of medical research, ultimately improving the quality of healthcare and advancing medical science."}},"id":135299,"acronym":"VAL_JC - MOON","mainTitle":"EndoMetriosis Organoids to vOice up woman paiN.","mainDescription":"Endometriosis is a chronic and debilitating condition that affects approximately 10% of reproductive-aged women worldwide. It occurs when the tissue that usually lines the inside of the uterus, known as the endometrium, grows outside the uterus, such as in the peritoneum, ovaries, fallopian tubes, or other areas in the pelvis. This misplaced tissue can cause severe pain, infertility, and other complications. Endometriosis remains poorly understood despite its prevalence, and current treatment options are often inadequate. Developing a more accurate and effective model to study endometriosis is essential to advance our understanding of the condition and develop better therapies.\r\n\r\nThe Moon project aims to develop a sophisticated in vitro biochip platform that accurately mimics the cyclical changes of the endometrium under the influence of hormones. This biochip consists of three interconnected modules, each dedicated to simulating different aspects of the female reproductive system, specifically emphasising endometriosis. By providing a more accurate model of the female reproductive organs and improving our understanding of endometriosis, this project will allow researchers to identify new drug targets and biomarkers, ultimately leading to better patient treatments.\r\n\r\nIn addition, the Moon project could foster HES-SO collaborations among different sectors, such as pharmaceutical companies, biotech organisations, and academic institutions, to develop new treatments and therapies for endometriosis. Moreover, this interdisciplinary approach may pave the way for creating similar projects in other areas of medical research, ultimately improving the quality of healthcare and advancing medical science.","value":"16500.00","finished":false,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1837163,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"HEPIA inTECH","class":"academique"}],"collaborators":[{"id":7765592,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":135299}],"dataHub":true,"startAt":"2024-11-27T00:00:00+01:00","endAt":"2025-10-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7764634,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":9250,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":9251,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":9252,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":48805,"acronym":"SCAHT-5","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"168095.23","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7764632,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":48805},{"id":7764633,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":48805},{"id":7764634,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":48805},{"id":7764635,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":48805}],"dataHub":true,"startAt":"2015-01-01T00:00:00+01:00","endAt":"2015-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7760351,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":12466,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":12467,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":12468,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":94184,"acronym":"SCAHT-9","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"240000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7760349,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":94184},{"id":7760350,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":94184},{"id":7760351,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":94184},{"id":7760352,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"axel.baxarias","project":94184},{"id":7760353,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"yoann.muller","project":94184},{"id":7760354,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":94184},{"id":7760355,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"julien.crovador","project":94184},{"id":7760356,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":94184}],"dataHub":true,"startAt":"2019-01-01T00:00:00+01:00","endAt":"2019-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7757546,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":{"translations":{"fr":{"id":10438,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":10439,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":10440,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":66944,"acronym":"SCAHT-7","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"240000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7757544,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":66944},{"id":7757545,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":66944},{"id":7757546,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":66944},{"id":7757547,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":66944}],"dataHub":true,"startAt":"2017-01-01T00:00:00+01:00","endAt":"2017-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

[{"id":10873981706,"position":-1,"master":1,"function":"Professeur HES associ\u00e9","title":null,"email":"adrien.roux@hesge.ch","display":true,"jobLocation":"Campus Biotech - B3-02 218.118","phone":"+41 22 558 50 13","phoneVisible":false,"employer":{"translations":{"fr":{"id":23,"name":"Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture de Gen\u00e8ve"}},"id":561,"ldapId":"RORG-HEGE-EPIA","abbreviation":"hepia","link":"http:\/\/www.hesge.ch\/hepia","mail":"RHHEPIA@hesge.ch ","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/logo_hepia-ge.png","gmap":"46.209551, 6.135261","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1054,"type":"adressePrincipale","street":"Rue de la Prairie 4","officeBox":"","country":"CH","city":"1202 Gen\u00e8ve"}],"mainDomain":null,"secondaryDomain":null,"programs":[{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},{"id":22,"empty":false,"name":"BSc HES-SO en G\u00e9nie m\u00e9canique"},{"id":24,"empty":false,"name":"BSc HES-SO en G\u00e9nie civil"},{"id":26,"empty":false,"name":"BA HES-SO en Architecture"},{"id":49,"empty":false,"name":"BSc HES-SO en Technique des b\u00e2timents"},{"id":50,"empty":false,"name":"BSc HES-SO en Ing\u00e9nierie des technologies de l'information"},{"id":51,"empty":false,"name":"BSc HES-SO en Gestion de la nature"},{"id":52,"empty":false,"name":"BSc HES-SO en Architecture du paysage"},{"id":53,"empty":false,"name":"BSc HES-SO en Agronomie"},{"id":79,"empty":false,"name":"BSC HES-SO en Informatique et syst\u00e8mes de communication"},{"id":80,"empty":false,"name":"BSc en Informatique et syst\u00e8mes de communication"}]},"instituts":[],"service":{"translations":{"fr":{"id":23,"name":"Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture de Gen\u00e8ve"}},"id":561,"ldapId":"RORG-HEGE-EPIA","abbreviation":"hepia","link":"http:\/\/www.hesge.ch\/hepia","mail":"RHHEPIA@hesge.ch ","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/logo_hepia-ge.png","gmap":"46.209551, 6.135261","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1054,"type":"adressePrincipale","street":"Rue de la Prairie 4","officeBox":"","country":"CH","city":"1202 Gen\u00e8ve"}],"mainDomain":null,"secondaryDomain":null,"programs":[{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},{"id":22,"empty":false,"name":"BSc HES-SO en G\u00e9nie m\u00e9canique"},{"id":24,"empty":false,"name":"BSc HES-SO en G\u00e9nie civil"},{"id":26,"empty":false,"name":"BA HES-SO en Architecture"},{"id":49,"empty":false,"name":"BSc HES-SO en Technique des b\u00e2timents"},{"id":50,"empty":false,"name":"BSc HES-SO en Ing\u00e9nierie des technologies de l'information"},{"id":51,"empty":false,"name":"BSc HES-SO en Gestion de la nature"},{"id":52,"empty":false,"name":"BSc HES-SO en Architecture du paysage"},{"id":53,"empty":false,"name":"BSc HES-SO en Agronomie"},{"id":79,"empty":false,"name":"BSC HES-SO en Informatique et syst\u00e8mes de communication"},{"id":80,"empty":false,"name":"BSc en Informatique et syst\u00e8mes de communication"}]},"serviceHesso":null,"branch":{"translations":{"fr":{"id":364,"name":"Microtechniques"}},"id":139430,"abbreviation":"MTEC","type":1,"ldapId":"RACA-TICO-MTEC","parent":{"translations":{"fr":{"id":637,"name":"Technique et IT"}},"id":56625318,"abbreviation":"TeIT","type":0,"ldapId":"RACA-TICO","parent":null}}}]

{"id":151,"type":"linkedin","url":"https:\/\/www.linkedin.com\/in\/adrienroux\/"}

{"id":152,"type":"orcid","url":"https:\/\/orcid.org\/0000-0001-7618-6129"}

{"id":153,"type":"researchgate","url":"https:\/\/www.researchgate.net\/profile\/Adrien_Roux2"}

{"id":406,"type":"link","url":"https:\/\/www.hesge.ch\/hepia\/en\/group\/tissue-engineering"}

{"id":1078338,"translations":[],"program":{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},"programText":"15","level":null,"url":null,"display":true,"dataHub":false,"position":0,"unit":{"translations":{"fr":{"id":23,"name":"Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture de Gen\u00e8ve"}},"id":561,"ldapId":"RORG-HEGE-EPIA","abbreviation":"hepia","link":"http:\/\/www.hesge.ch\/hepia","mail":"RHHEPIA@hesge.ch ","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/logo_hepia-ge.png","gmap":"46.209551, 6.135261","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1054,"type":"adressePrincipale","street":"Rue de la Prairie 4","officeBox":"","country":"CH","city":"1202 Gen\u00e8ve"}],"mainDomain":null,"secondaryDomain":null,"programs":[{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},{"id":22,"empty":false,"name":"BSc HES-SO en G\u00e9nie m\u00e9canique"},{"id":24,"empty":false,"name":"BSc HES-SO en G\u00e9nie civil"},{"id":26,"empty":false,"name":"BA HES-SO en Architecture"},{"id":49,"empty":false,"name":"BSc HES-SO en Technique des b\u00e2timents"},{"id":50,"empty":false,"name":"BSc HES-SO en Ing\u00e9nierie des technologies de l'information"},{"id":51,"empty":false,"name":"BSc HES-SO en Gestion de la nature"},{"id":52,"empty":false,"name":"BSc HES-SO en Architecture du paysage"},{"id":53,"empty":false,"name":"BSc HES-SO en Agronomie"},{"id":79,"empty":false,"name":"BSC HES-SO en Informatique et syst\u00e8mes de communication"},{"id":80,"empty":false,"name":"BSc en Informatique et syst\u00e8mes de communication"}]},"unitText":"561","executions":[{"id":115,"languages":["fr","en","de"],"allLanguages":true,"execution":{"id":111,"year":null,"semester":null,"branch":null,"slug":"95b0608342ab71c656657dd19d2165f1","title":"Biologie"}}]}

{"id":1047484,"translations":[],"program":{"id":57,"name":"MSc HES-SO en Engineering","empty":false},"programText":"57","level":null,"url":null,"display":true,"dataHub":false,"position":0,"unit":{"translations":{"fr":{"id":4,"name":"HES-SO Master"}},"id":514047574,"ldapId":"RORG-MASO","abbreviation":"SO Master","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1048,"type":"adressePrincipale","street":"Av. de Provence 6","officeBox":"","country":"CH","city":"1007 Lausanne"}],"mainDomain":null,"secondaryDomain":null,"link":"http:\/\/www.hes-so.ch\/masters","mail":"rh@hes-so.ch","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/\/units-logos\/hes_so_logo_rgb-63a08f56cfb2b.png","gmap":"46.523196, 6.610416","programs":[{"id":54,"empty":false,"name":"MSc HES-SO\/UNIL en sciences infirmi\u00e8res"},{"id":55,"empty":false,"name":"MSc HES-SO en Business Administration"},{"id":56,"empty":false,"name":"MSc HES-SO en Life Sciences"},{"id":57,"name":"MSc HES-SO en Engineering","empty":false},{"id":58,"empty":false,"name":"MA BFH\/HES-SO en Architecture"},{"id":59,"empty":false,"name":"MSc HES-SO en Integrated Innovation for Product and Business Development - Innokick"},{"id":60,"empty":false,"name":"MSc HES-SO\/UNIL en Sciences de la sant\u00e9"},{"id":61,"empty":false,"name":"MA HES-SO en Travail social"},{"id":74,"empty":false,"name":"MSc HES-SO en Ing\u00e9nierie du territoire"},{"id":75,"empty":false,"name":"MSc UNIGE\/HES-SO en D\u00e9veloppement territorial"}]},"unitText":"514047574","executions":[{"id":116,"languages":["fr","en","de"],"allLanguages":true,"execution":{"id":111,"year":null,"semester":null,"branch":null,"slug":"95b0608342ab71c656657dd19d2165f1","title":"Biologie"}}]}

{"id":1003463,"translations":[],"program":{"id":57,"name":"MSc HES-SO en Engineering","empty":false},"programText":"57","level":null,"url":null,"display":true,"dataHub":false,"position":0,"unit":{"translations":{"fr":{"id":4,"name":"HES-SO Master"}},"id":514047574,"ldapId":"RORG-MASO","abbreviation":"SO Master","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1048,"type":"adressePrincipale","street":"Av. de Provence 6","officeBox":"","country":"CH","city":"1007 Lausanne"}],"mainDomain":null,"secondaryDomain":null,"link":"http:\/\/www.hes-so.ch\/masters","mail":"rh@hes-so.ch","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/\/units-logos\/hes_so_logo_rgb-63a08f56cfb2b.png","gmap":"46.523196, 6.610416","programs":[{"id":54,"empty":false,"name":"MSc HES-SO\/UNIL en sciences infirmi\u00e8res"},{"id":55,"empty":false,"name":"MSc HES-SO en Business Administration"},{"id":56,"empty":false,"name":"MSc HES-SO en Life Sciences"},{"id":57,"name":"MSc HES-SO en Engineering","empty":false},{"id":58,"empty":false,"name":"MA BFH\/HES-SO en Architecture"},{"id":59,"empty":false,"name":"MSc HES-SO en Integrated Innovation for Product and Business Development - Innokick"},{"id":60,"empty":false,"name":"MSc HES-SO\/UNIL en Sciences de la sant\u00e9"},{"id":61,"empty":false,"name":"MA HES-SO en Travail social"},{"id":74,"empty":false,"name":"MSc HES-SO en Ing\u00e9nierie du territoire"},{"id":75,"empty":false,"name":"MSc UNIGE\/HES-SO en D\u00e9veloppement territorial"}]},"unitText":"514047574","executions":[{"id":117,"languages":["fr","en","de"],"allLanguages":true,"execution":{"id":110,"year":null,"semester":null,"branch":null,"slug":"0d923649354f8e687d3567a6ef2206e0","title":"Bio-Ing\u00e9nierie"}}]}

{"id":1001675,"translations":[],"program":{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},"programText":"15","level":null,"url":null,"display":true,"dataHub":false,"position":0,"unit":{"translations":{"fr":{"id":23,"name":"Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture de Gen\u00e8ve"}},"id":561,"ldapId":"RORG-HEGE-EPIA","abbreviation":"hepia","link":"http:\/\/www.hesge.ch\/hepia","mail":"RHHEPIA@hesge.ch ","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/logo_hepia-ge.png","gmap":"46.209551, 6.135261","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1054,"type":"adressePrincipale","street":"Rue de la Prairie 4","officeBox":"","country":"CH","city":"1202 Gen\u00e8ve"}],"mainDomain":null,"secondaryDomain":null,"programs":[{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},{"id":22,"empty":false,"name":"BSc HES-SO en G\u00e9nie m\u00e9canique"},{"id":24,"empty":false,"name":"BSc HES-SO en G\u00e9nie civil"},{"id":26,"empty":false,"name":"BA HES-SO en Architecture"},{"id":49,"empty":false,"name":"BSc HES-SO en Technique des b\u00e2timents"},{"id":50,"empty":false,"name":"BSc HES-SO en Ing\u00e9nierie des technologies de l'information"},{"id":51,"empty":false,"name":"BSc HES-SO en Gestion de la nature"},{"id":52,"empty":false,"name":"BSc HES-SO en Architecture du paysage"},{"id":53,"empty":false,"name":"BSc HES-SO en Agronomie"},{"id":79,"empty":false,"name":"BSC HES-SO en Informatique et syst\u00e8mes de communication"},{"id":80,"empty":false,"name":"BSc en Informatique et syst\u00e8mes de communication"}]},"unitText":"561","executions":[{"id":114,"languages":["fr","en","de"],"allLanguages":true,"execution":{"id":110,"year":null,"semester":null,"branch":null,"slug":"0d923649354f8e687d3567a6ef2206e0","title":"Bio-Ing\u00e9nierie"}}]}

{"id":1095573,"translations":[],"program":null,"programText":"Master en sciences biom\u00e9dicales","level":null,"url":null,"display":true,"dataHub":false,"position":1,"unit":null,"unitText":"UNIGE","executions":[{"id":1179,"languages":["fr","en","de"],"allLanguages":true,"execution":{"id":883,"year":null,"semester":null,"branch":null,"slug":"326001434b5394d42d52d186a6f4a8cb","title":"Technologie m\u00e9dicale HS001"}},{"id":1180,"languages":["fr","en","de"],"allLanguages":true,"execution":{"id":884,"year":null,"semester":null,"branch":null,"slug":"7589c9289c58007a1bc8244ed64a032a","title":"Parcours d'un dispositif m\u00e9dical \/ 14HS002"}}]}

{"id":295,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":241,"name":"Bio-engineering"}}

{"id":296,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":242,"name":"Biology"}}

{"id":297,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":243,"name":"In vitro cell culture"}}

{"id":298,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":244,"name":"Tissue Engineering"}}

{"id":299,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":245,"name":"Biocompatibilit\u00e9"}}

{"id":300,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":246,"name":"Organ-on-chip"}}

{"id":301,"languages":["fr","en","de"],"allLanguages":true,"skill":{"id":247,"name":"Biochip"}}

Ecole(s)

HEPIA

Affichage téléphone

0